The impact of circumferential tumour location on the clinical outcome of rectal cancer patients managed with neoadjuvant chemoradiotherapy followed by total mesorectal excision
- PMID: 32113887
- DOI: 10.1016/j.ejso.2020.02.034
The impact of circumferential tumour location on the clinical outcome of rectal cancer patients managed with neoadjuvant chemoradiotherapy followed by total mesorectal excision
Abstract
Aim: To investigate the impact of circumferential tumour location on neoadjuvant chemoradiotherapy (CRT) response and its prognostic value for locally advanced rectal cancer (LARC) patients after CRT and surgery.
Methods: A retrospective study was performed on 486 patients with LARC who received neoadjuvant CRT and surgical treatment. The rate of pathological complete response (pCR) and survival among patients with anteriorly, laterally, and posteriorly located tumours were compared. Logistic regression was performed to identify pCR predictors.
Results: The anterior tumours exhibited the highest pCR rate of 26.7%, which was slightly higher than the 20.0% and 12.3% for lateral and posterior tumours, respectively (P = 0.006). The 5-year Overall survival (OS) rates after CRT were similar among the anterior, lateral, and posterior groups (anterior vs lateral vs posterior: 81.1% vs 89.9% vs 84.1%, P = 0.6368). Multivariate analysis revealed that the circumferential tumour location, post-CRT serum CEA and post-CRT tumour thickness measured by MRI were independently correlated with achieving pCR.
Conclusion: This study is the first, to the best of our knowledge, to show that anterior LARC exhibited the highest pCR rate after neoadjuvant CRT. Patients with anterior rectal cancers do not have different prognoses from those with non-anterior cancers if they undergo neoadjuvant CRT.
Keywords: Circumferential tumour location; Locally advanced rectal cancer; Pathological complete response.
Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors have no conflicts of interest to declare.
Comment in
-
Reply to: The impact of circumferential tumor location on the clinical outcomes of rectal cancers receiving neoadjuvant chemoradiation and surgery-does is really matter?Eur J Surg Oncol. 2020 Dec;46(12):2341-2342. doi: 10.1016/j.ejso.2020.07.024. Epub 2020 Jul 29. Eur J Surg Oncol. 2020. PMID: 32771249 No abstract available.
-
The impact of circumferential tumor location on the clinical outcomes of rectal cancers receiving neoadjuvant chemoradiation and surgery-does it really matter?Eur J Surg Oncol. 2020 Dec;46(12):2339-2340. doi: 10.1016/j.ejso.2020.07.023. Epub 2020 Jul 28. Eur J Surg Oncol. 2020. PMID: 32771250 No abstract available.
Similar articles
-
Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).BMC Cancer. 2018 May 8;18(1):538. doi: 10.1186/s12885-018-4466-7. BMC Cancer. 2018. PMID: 29739356 Free PMC article.
-
Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer.Eur J Surg Oncol. 2018 Jul;44(7):1013-1017. doi: 10.1016/j.ejso.2018.03.014. Epub 2018 Mar 23. Eur J Surg Oncol. 2018. PMID: 29650419
-
Comparative Outcomes of Preoperative Chemoradiotherapy and Selective Postoperative Chemoradiotherapy in Clinical Stage T3N0 Low and Mid Rectal Cancer.J Invest Surg. 2019 Nov;32(7):679-687. doi: 10.1080/08941939.2018.1469696. Epub 2018 Sep 14. J Invest Surg. 2019. PMID: 30215538
-
Prognostic value of tumour regression grade in locally advanced rectal cancer: a systematic review and meta-analysis.Colorectal Dis. 2018 Jul;20(7):574-585. doi: 10.1111/codi.14106. Epub 2018 May 8. Colorectal Dis. 2018. PMID: 29582537
-
Complete response after neoadjuvant therapy in rectal cancer: to operate or not to operate?Dig Dis. 2012;30 Suppl 2:109-17. doi: 10.1159/000342039. Epub 2012 Nov 23. Dig Dis. 2012. PMID: 23207942 Review.
Cited by
-
The multifaceted role of Fragile X-Related Protein 1 (FXR1) in cellular processes: an updated review on cancer and clinical applications.Cell Death Dis. 2024 Jan 18;15(1):72. doi: 10.1038/s41419-023-06413-8. Cell Death Dis. 2024. PMID: 38238286 Free PMC article. Review.
-
Stealth Nanocarriers in Cancer Therapy: a Comprehensive Review of Design, Functionality, and Clinical Applications.AAPS PharmSciTech. 2024 Jun 18;25(6):140. doi: 10.1208/s12249-024-02843-5. AAPS PharmSciTech. 2024. PMID: 38890191 Review.
-
The progressive trend of modeling and drug screening systems of breast cancer bone metastasis.J Biol Eng. 2024 Feb 5;18(1):14. doi: 10.1186/s13036-024-00408-5. J Biol Eng. 2024. PMID: 38317174 Free PMC article. Review.
-
Targeting ferroptosis regulators by natural products in colorectal cancer.Front Pharmacol. 2024 May 27;15:1374722. doi: 10.3389/fphar.2024.1374722. eCollection 2024. Front Pharmacol. 2024. PMID: 38860170 Free PMC article. Review.
-
Melatonin for gastric cancer treatment: where do we stand?Naunyn Schmiedebergs Arch Pharmacol. 2025 Feb;398(2):1265-1282. doi: 10.1007/s00210-024-03451-7. Epub 2024 Sep 17. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 39287677 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials